Ontario Fast-Tracking Access to Six Breakthrough Cancer Drugs

January 23, 2026

Our government is protecting Ontario’s health-care system and leading the world in cancer care by approving access to the first six new life-extending cancer treatments through the Faster Access to Specialized Treatments (FAST) program.

This first-in-Canada initiative is fast-tracking access to breakthrough cancer drugs, giving patients in need faster access to life-changing treatment options, and continuing to connect patients to life-saving cancer treatments almost a full year sooner as part of our government’s plan to protect Ontario’s health-care system.

For every Ontarian facing a cancer diagnosis, timely access to high-quality treatment can make all the difference. Through the FAST program, we’re accelerating access to life-saving treatment across the province, bringing transformative care to those who need it most, including the following six life-saving treatments:

• TAGRISSO: Used to treat lung cancer

• SCEMBLIX: Used to treat a type of leukemia

• NUBEQA: Used to treat prostate cancer

• CALQUENCE: Used to treat lymphoma

• OPDIVO with YERVOY: Combination therapy used to treat a type of colorectal cancer

• OPDIVO with YERVOY: Combination therapy used to treat a type of liver cancer

Building on this momentum, the FAST program will continue to fast-track additional cancer drug approvals in the coming months and expedite access to seven to ten high-priority cancer drugs every year, helping Ontario patients receive publicly funded treatments up to one year sooner.

Through Your Health: A Plan for Connected and Convenient Care, our government continues to modernize the health-care system and expand access to critical services, ensuring patients receive the right care, at the right time.

Learn More: https://news.ontario.ca/en/release/1006950/ontario-fast-tracking-access-to-six-breakthrough-cancer-drugs